← Alle mensen

ER

Eleonora Restuccia

7 publicaties

PubMed → Google Scholar →

Publicaties op Oncologisch.com

Predicting ovarian function loss after chemotherapy and anti-HER2 therapy in young breast cancer patients.

Journal of the National Cancer Institute · 1 november 2025

Overleving met trastuzumab-emtansine bij residueel HER2-positief mammacarcinoom: KATHERINE definitieve OS

The New England journal of medicine · 16 januari 2025

Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the A...

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024-11

Atezolizumab plus neoadjuvante anti-HER2 en chemotherapie bij HER2-positief mammacarcinoom: IMpassion050 fase III

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 1 september 2022

Adjuvant pertuzumab-trastuzumab bij HER2-positief mammacarcinoom: APHINITY zesjaars

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 1 mei 2021

Subcutaan pertuzumab-trastuzumab plus chemotherapie: FeDeriCa fase III

The Lancet. Oncology · 2021-01

Pertuzumab-trastuzumab-docetaxel bij HER2-positief gemetastaseerd mammacarcinoom: CLEOPATRA definitieve OS

The Lancet. Oncology · 2020-04